Warfarin: The End or the End of One Size Fits All Therapy?

Pirmohamed, Munir ORCID: 0000-0002-7534-7266 (2018) Warfarin: The End or the End of One Size Fits All Therapy? JOURNAL OF PERSONALIZED MEDICINE, 8 (3). E22-.

Text warfarin revised clean.pdf - Author Accepted Manuscript Download (235kB)

Abstract

Oral anticoagulants are required for both treatment and prophylaxis in many different diseases. Clinicians and patients now have a choice of oral anticoagulants, including the vitamin K antagonists (of which warfarin is the most widely used and is used as the exemplar in this paper), and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban, and edoxaban). This paper explores the recent advances and controversies in oral anticoagulation. While some commentators may favour a complete switchover to DOACs, this paper argues that warfarin still has a place in therapy, and a stratified approach that enables the correct choice of both drug and dose would improve both patient outcomes and affordability.

Item Type:	Article
Uncontrolled Keywords:	warfarin, vitamin K antagonists, direct oral anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, pharmacogenomics, personalized medicine, therapeutic drug monitoring
Depositing User:	Symplectic Admin
Date Deposited:	15 Aug 2018 10:29
Last Modified:	07 Feb 2024 05:18
DOI:	10.3390/jpm8030022
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3025053